• Phoenix Financial recently acquired more than 3.5 million additional shares of Teva Pharmaceutical Industries in the third quarter, elevating its stake to 41.3 million shares valued at US$834.2 million and making Teva the fund’s second-largest holding at 6.8% of its reportable assets.

  • This move signals institutional confidence in Teva’s turnaround plan, particularly its focus on debt reduction, cost savings, and growing its biosimilar and complex generics portfolio.

  • We’ll examine how this significant increase in institutional ownership could influence the outlook for Teva’s ongoing turnaround strategy.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump’s tariffs. Discover why before your portfolio feels the trade war pinch.

To own shares of Teva Pharmaceutical Industries today, you need conviction in its turnaround strategy: ongoing debt reduction, cost savings, and execution on high-value biosimilar and branded drug launches. Phoenix Financial’s expanded stake is a high-profile vote of confidence but does not materially change the near-term story, the biggest risk remains heavy debt, while the most important catalyst is the ramp of core products like AUSTEDO and new biosimilars.

Of the company’s recent announcements, the European launch of the Ranivisio® Lucentis biosimilar stands out, supporting the proposition that biosimilar adoption can drive incremental, higher-margin revenues to counteract stagnant generics. This milestone reinforces management’s plan to reshape the business for profitability and margin growth, key levers for future shareholder returns even as other risks linger.

However, investors should also be aware that the scale of Teva’s debt burden continues to weigh on its ability to…

Read the full narrative on Teva Pharmaceutical Industries (it’s free!)

Teva Pharmaceutical Industries’ outlook forecasts $17.8 billion in revenue and $1.5 billion in earnings by 2028. Achieving this would require 2.3% annual revenue growth and an increase in earnings of about $1.7 billion from the current -$157 million.

Uncover how Teva Pharmaceutical Industries’ forecasts yield a $24.44 fair value, a 19% upside to its current price.

TEVA Community Fair Values as at Nov 2025 TEVA Community Fair Values as at Nov 2025

Fourteen Simply Wall St Community members see Teva’s fair value in a wide range, from US$24.44 to US$58.33 per share. This spread highlights that while some anticipate outsized returns, ongoing execution on cost savings and biosimilar launches remains critical to closing the gap.

Explore 14 other fair value estimates on Teva Pharmaceutical Industries – why the stock might be worth just $24.44!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

  • A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 5 key rewards that could impact your investment decision.

  • Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Teva Pharmaceutical Industries’ overall financial health at a glance.

Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include TEVA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com